NCT00921661CompletedPhase 1
A Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Aflibercept in Combination With Intravenous Irinotecan/5-fluorouracil/Isovorin (FOLFIRI) Administered Every 2 Weeks in Patients With Metastatic Colorectal Cancer
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Sanofi
- Enrollment
- 16
- Locations
- 1
- Primary Endpoint
- Dose-limiting toxicity (DLT) combination with FOLFIRI
Study Overview
Brief Summary
The primary objective is to determine the dose of aflibercept to be further studied in combination with irinotecan/5-fluorouracil/isovorin (FOLFIRI) in Japanese patients with metastatic colorectal cancer.
Secondary objectives of this study are to assess the safety profile of aflibercept, to determine the pharmacokinetics of aflibercept, to make a preliminary assessment of antitumor effects.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 20 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients with histologically or cytologically proven malignant tumor of the colon or rectum which is metastatic and inoperable.
- •Patients must have received at least one prior line of treatment with any standard of care, who have failed the treatment, or who have not been eligible for standard of care for safety reasons.
Exclusion Criteria
- •Treatment with chemotherapy, hormone therapy, radiotherapy, surgery, blood products, or any investigational agent within 28 days.
- •ECOG Performance Status>1
- •Anticipated need for a major surgical procedure or radiation therapy during the study.
- •Uncontrolled malignant ascites.
- •History of brain metastases, spinal cord compression, or carcinomatous meningitis or new evidence of brain or leptomeningeal disease on screening CT or MRI scan.
- •Pregnant or breast-feeding women.
- •Uncontrolled hypertension
- •Patients who have previously been treated with aflibercept
- •History of abdominal fistula, GI perforation, or intra-abdominal abscess within the past 28 days.
- •History of hypersensitivity to any recombinant proteins, irinotecan, fluoropyrimidine or isovorin.
- •Known dihydropyrimidine dehydrogenase deficiency.
- •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Arms & Interventions
AVE0005 (aflibercept)
Experimental
Intervention: AVE0005 (aflibercept) (Drug)
Outcomes
Primary Outcomes
Dose-limiting toxicity (DLT) combination with FOLFIRI
Time Frame: During the first 2 cycles (4 weeks) of study treatment
Secondary Outcomes
- physical examination, laboratory safety tests, adverse events(up to 60 days after last treatment)
- Pharmacokinetics(up to 90 days after last treatment)
- Tumor burden, endogenous free VEGF(every 3 cycles)
- Immunogenicity(up to 90 days after last treatment)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
A Phase I Study of Intravenous Aflibercept in Combination With Docetaxel in Japanese Cancer PatientsNeoplasmsNCT00545246Sanofi12
Completed
Phase 1
A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid TumorsNeoplasm MalignantNCT01148615Sanofi20
Completed
Phase 1
Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell LymphomaLymphoma, Non-HodgkinNCT00644124Sanofi25
Completed
Phase 1
A Safety Study of LY3372689 in Healthy ParticipantsHealthyNCT04106206Eli Lilly and Company54
Completed
Phase 2
Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular DegenerationNeovascular (Wet) Age-Related Macular DegenerationNCT04126317Regeneron Pharmaceuticals106